258 related articles for article (PubMed ID: 37942277)
1. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
[TBL] [Abstract][Full Text] [Related]
2. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Charles-Schoeman C; Buch MH; Dougados M; Bhatt DL; Giles JT; Ytterberg SR; Koch GG; Vranic I; Wu J; Wang C; Kwok K; Menon S; Rivas JL; Yndestad A; Connell CA; Szekanecz Z
Ann Rheum Dis; 2023 Jan; 82(1):119-129. PubMed ID: 36137735
[TBL] [Abstract][Full Text] [Related]
3. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Curtis JR; Yamaoka K; Chen YH; Bhatt DL; Gunay LM; Sugiyama N; Connell CA; Wang C; Wu J; Menon S; Vranic I; Gómez-Reino JJ
Ann Rheum Dis; 2023 Mar; 82(3):331-343. PubMed ID: 36600185
[TBL] [Abstract][Full Text] [Related]
4. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Balanescu AR; Citera G; Pascual-Ramos V; Bhatt DL; Connell CA; Gold D; Chen AS; Sawyerr G; Shapiro AB; Pope JE; Schulze-Koops H
Ann Rheum Dis; 2022 Nov; 81(11):1491-1503. PubMed ID: 35922124
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR; Bhatt DL; Mikuls TR; Koch GG; Fleischmann R; Rivas JL; Germino R; Menon S; Sun Y; Wang C; Shapiro AB; Kanik KS; Connell CA;
N Engl J Med; 2022 Jan; 386(4):316-326. PubMed ID: 35081280
[TBL] [Abstract][Full Text] [Related]
7. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
Kristensen LE; Strober B; Poddubnyy D; Leung YY; Jo H; Kwok K; Vranic I; Fleishaker DL; Fallon L; Yndestad A; Gladman DD
Ther Adv Musculoskelet Dis; 2023; 15():1759720X221149965. PubMed ID: 36777695
[TBL] [Abstract][Full Text] [Related]
8. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
11. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
12. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE; Danese S; Yndestad A; Wang C; Nagy E; Modesto I; Rivas J; Benda B
Ann Rheum Dis; 2023 Jul; 82(7):901-910. PubMed ID: 36931693
[TBL] [Abstract][Full Text] [Related]
13. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
Dikranian A; Gold D; Bessette L; Nash P; Azevedo VF; Wang L; Woolcott J; Shapiro AB; Szumski A; Fleishaker D; Wollenhaupt J
Rheumatol Ther; 2022 Apr; 9(2):411-433. PubMed ID: 34921355
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
Kristensen LE; Deodhar A; Leung YY; Vranic I; Mortezavi M; Fallon L; Yndestad A; Kinch CD; Gladman DD
Rheumatol Ther; 2024 Jun; 11(3):487-499. PubMed ID: 38696034
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
[TBL] [Abstract][Full Text] [Related]
17. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study.
Cho SK; Song YJ; Kim HW; Nam E; Jeon JY; Yoo HJ; Sung YK
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38366621
[TBL] [Abstract][Full Text] [Related]
19. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
